Condition: Meningioma · Sponsor: Exelixis
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
This description comes directly from the study's public registry record.
Exelixis Clinical Trials · 1-888-EXELIXIS (888-393-5494) · druginfo@exelixis.com
Backup or International · 650-837-7400
Always discuss trial participation with your own doctor first.
| University of Alabama | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic_Arizona | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic_Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Baptist Health Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | Recruiting |
| Mayo Clinic_Rochester | Rochester, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| UT Health San Antonio Mays Cancer Center | San Antonio, Texas, United States | Recruiting |
| Inova Center for Personalized Health | Fairfax, Virginia, United States | Recruiting |
| UW Carbone Cancer Center | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07428616